ZSZequn Sun

Zequn Sun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zequn Sun has a total of 93 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of Smoking on Treatment Outcomes in Patients With Human Papillomavirus‐Related Oropharyngeal Cancer

    by Michelle M. Kwan, Latifa A. Bazzi, Zequn Sun, Dayton Rand, Asher Park, Shravan Asthana, Alexis Larson, Poonam Yadav, Bharat B. Mittal, Adil Akthar, et al.

    Background: Patients with HPV+ oropharyngeal cancer (OPC) have worse outcomes with longer smoking history (≥ 10 pack‐years). This has been confirmed in trials of primary radiotherapy but not surgery, suggesting differential smoking impact by treatment received. We assessed smoking‐related outcomes at a single institution. Methods: Kaplan–Meier and Cox proportional hazards regression compared < 10 versus ≥ 10 pack‐years by treatment received for progression‐free survival (PFS) and overall survival (OS). Results: Smoking was associated with worse PFS in both primary (chemo)radiation (HR = 1.73 [1.12–2.69], p = 0.01) and primary surgery cohorts (HR = 1.77 [1.02–3.07], p = 0.04). In surgery patients, this association was attenuated after adjusting for socioeconomic indicators (HR = 1.69 [0.97–2.93], p = 0.06). On recursive partitioning analysis , ≥ 25 pack‐years was associated with worse PFS and OS overall and among radiotherapy patients. Conclusions: Smoking impacts outcomes in HPV + OPC regardless of treatment modality. Treatment‐specific differences in prior randomized studies may reflect underlying differences in patient characteristics. ≥ 25 pack‐years was associated with worse outcomes.

  • Open Access

    Negative Predictive Value of a Prostate MRI in Black Men: Implications for Biopsy Decision-Making

    by Sarah Sandlow, Samuel Carbunaru, Zequn Sun, Bernice Ofori, Yingzhe Liu, Eric Li, Courtney M. P. Hollowell, Patricia Vidal, Kent T. Perry, Hiten D. Patel, et al.

    Prostate Imaging Reporting and Data System (PIRADS) v2.1 scoring with multiparametric MRI (mpMRI) has a pooled 90% negative predictive value (NPV). PSA density (PSAD) ≤0.15ng/ml/cm3 has been shown to enhance mpMRI's NPV in non-Black men. Populations with higher disease prevalence are known to have lower NPVs. Given that Black men have higher PCa prevalence, we evaluate sensitivity and NPV of mpMRI in Black vs. non-Black men to assess possible mpMRI performance differences. As an exploratory objective, we investigate PSAD thresholds providing ≥90% sensitivity in Black men. We prospectively recruited Black and non-Black men referred to outpatient urology clinics for abnormal PSA or prostate exam in three similar biomarker validation studies from 2017-23 before MRI-informed diagnostic prostate biopsy. We combined the research cohorts with a retrospective clinical cohort of clinically similar Black and non-Black men from one academic institution who also underwent mpMRIs and MRI-informed biopsies. MRIs were scored using PIRADS version 2.0 or 2.1. Our analysis included 286 Black men and 965 non-Black men with PSA ≤15.0ng/ml. PIRADS <3 had an NPV of 77.1% versus 87.6% and a sensitivity of 90.7% vs. 96.3% for GG2-5 PCa in Black versus non-Black men, respectively (both p <0.05). Using PSAD ≥0.09 for Black men with PIRADS 1-2 lesions increased sensitivity to 92.9%. PIRADS <3 has a lower NPV and sensitivity in Black men. For negative prostate MRIs, PSAD ≥0.09 may be a better threshold for safe biopsy deferral in Black men to maintain a ≥90% sensitivity.


  • Open Access

    Prognostic impact of extranodal disease on PET/CT in follicular lymphoma: results from a validation study with ECOG 2408

    by Frederique St-Pierre, Stephen M. Broski, Zequn Sun, Masha Kocherginsky, Betsy LaPlant, Matthew J. Maurer, Andrew Quon, Lucia Baratto, Hatice Savas, Lale Kostakoglu, et al.


  • Financial Toxicity Screening Preferences in Patients With Breast Cancer

    by Laila A. Gharzai, Yingzhe (Alex) Liu, Zequn Sun, Leila J. Mady, Michelle Mohn, Alexis Larson, Sheetal Kircher, Betina Yanez, Ruth C. Carlos, John Pottow, et al.

    PURPOSE: Financial toxicity is an important issue in cancer that affects quality of life and treatment adherence. Screening can identify patients at risk but consensus on appropriate timing or methods is lacking. METHODS: We sent an anonymous survey to e-mail subscribers of a nationwide breast cancer–specific philanthropic organization in July 2023 asking about financial toxicity screening preferences. Frequencies, percentages, and medians were calculated for categorical and continuous variables. RESULTS: Of 5,774 potential participants, 738 respondents with a confirmed cancer diagnosis participated (12.7% response rate). Participants were 93% female (n = 690), had a median age of 50 years (IQR, 44-57), were 57% non-Hispanic White (n = 418), 20% Black/African-American (n = 149), 9.2% Hispanic (n = 68). 93% confirmed a breast cancer diagnosis (n = 689), and 54% were currently undergoing treatment (n = 400). Most indicated not being asked about financial stressors by (58%, n = 425) and not receiving assistance from their care team (68%, n = 498). Most preferred for providers to reach out regarding financial needs (83%, n = 615). Most wished for these discussions to take place early (when first diagnosed [45%, n = 334] or when treatment selected [37%, n = 275]) and to be asked frequently (each appointment [42%, n = 312] or once per month [36%, n = 268]). Participants felt most comfortable discussing financial needs with a social worker or patient/financial navigator (92%, n = 679), in person (75%, n = 553), or via telephone (65%, n = 479). CONCLUSION: Patients in this sample primarily consisting of women with breast cancer desired financial screening to occur early, often, and to be initiated by their providers. Patient preferences can inform optimal implementation of financial toxicity screening practices. Continued work refining best practices for financial toxicity screening should incorporate these patient preferences.


  • Validation of a Single Item Measure for Financial Toxicity Screening in Patients With Breast Cancer

    by Laila A. Gharzai, Leila J. Mady, Maria Armache, Zequn Sun, Reshma Jagsi, David Cella, J. Devin Peipert, Gelareh Sadigh, Richard W. Hass

    PURPOSE: Financial toxicity (FT) has been linked to higher symptom burden and poorer clinical outcomes for patients with cancer. Despite the availability of validated tools to measure FT, a simple screen remains an unmet need. We evaluated item 12 (“My illness has been a financial hardship to my family and me”) of the COmprehensive Score for Financial Toxicity (COST) measure as a single-item FT screening measure. METHODS: In this secondary analysis, 711 patients with cancer (690 with breast cancer) were recruited via a web-based survey from a philanthropic organization. COST items 1-11 were scored according to Functional Assessment of Chronic Illness Therapy scoring guidelines, with lower scores indicating worse FT. Analyses focused on establishing a correlation, examining item properties, and sensitivity/specificity of item 12 relative to the total COST score. RESULTS: Item 12 had a correlation of r = 0.53 with the COST-11 score, and an increase of one point on item 12 is associated with a decrease of approximately three total points on the full scale ( b , 3.35; P < .001; adjusted R 2 , 0.28). Item analysis with the graded-response item in response theory modeling showed very good discrimination ( a , 2.096) for item 12, indicating that it can reliably distinguish between low and high FT in patients. Sensitivity ranged between 75.6% and 95.7% on all item 12 thresholds to screen positive for FT using two COST cutoffs as criteria. Maximizing both sensitivity and specificity was to be found for higher item 12 scores. CONCLUSION: To our knowledge, this is the first validation of a single-item screening measure for FT. Overall, these results illustrate that item 12 from the COST measure is a good candidate for a single-item screener. Clinicians can choose among item 12 screening thresholds depending on their tolerance for low specificity.


  • Open Access

    The Impact of Next-Generation Sequencing Workflows on Outcomes in Advanced Lung Cancer: A Retrospective Analysis at One Academic Health System

    by Chetan V. Vakkalagadda, Danielle B. Dressler, Zequn Sun, Joseph Fuchs, Yingzhe Liu, Philip Silberman, Avanthi Ragam, Sheetal Kircher, Jyoti D. Patel, Nisha A. Mohindra

    Purpose: Broad-based molecular testing with next-generation sequencing (NGS) is now the standard of care in advanced non-small cell lung cancer (NSCLC). Two approaches to molecular testing are (1) reflexive testing at pathologic NSCLC confirmation, often using an in-house molecular panel, and (2) send-out testing to private vendors, ordered by a clinician. This study explored the outcomes with reflex versus send-out testing. Methods: A retrospective chart review was conducted of patients diagnosed with de novo stage IV NSCLC in 2019 and 2020 at three hospitals in the same system, one academic hospital (Northwestern Memorial Hospital, or NMH) utilizing reflex, in-house NGS, and two community-based hospitals (Central DuPage Hospital, or CDH, and Delnor, or D) sending out tissue samples for testing. The outcomes assessed were the time from biopsy to results, biopsy to treatment, the incidence of first-line targetable mutations and the use of first-line targeted therapies, and overall survival. Results: In total, 191 patients met the inclusion criteria, 85 at NMH, 106 at CDH + D, and in total, 131 in 2019 and 60 in 2020. The time to results was significantly shorter with reflexive NGS when compared with send-out testing; the time to treatment was also shorter but not statistically significant. At CDH + D, the time to results was significantly shorter with a limited panel than with comprehensive testing, but the time to treatment was similar. NGS testing rates were 95% at NMH and 84.5% at CDH + D (p = 0.009), with 31.0% at NMH receiving 1L targeted therapies versus 20.8% at CDH + D (p = 0.08). In 2019, the median time from biopsy to treatment was 35 days at NMH and 38 days at CDH and Delnor; in 2020, time to treatment was 26 days and 37 days, respectively. Overall survival trended longer in 2020 relative to 2019 independent of site. Conclusion: Reflexive NGS testing is associated with a shorter time to actionable results and higher rates of first-line targetable mutations than send-out testing. In practices with send-out testing, limited panels had slightly faster turnaround times but no difference in time to treatment. If resources allow, reflexive NGS should be considered in healthcare systems for patients with NSCLC.


  • Open Access

    X-ray Fluorescence Microscopy to Develop Elemental Classifiers and Investigate Elemental Signatures in BALB/c Mouse Intestine a Week after Exposure to 8 Gy of Gamma Rays

    by Anthony Smith, Katrina Dobinda, Si Chen, Peter Zieba, Tatjana Paunesku, Zequn Sun, Gayle E. Woloschak

    Iron redistribution in the intestine after total body irradiation is an established phenomenon. However, in the literature, there are no reports about the use of X-ray fluorescence microscopy or equivalent techniques to generate semi-quantitative 2D maps of iron in sectioned intestine samples from irradiated mice. In this work, we used X-ray fluorescence microscopy (XFM) to map the elemental content of iron as well as phosphorus, sulfur, calcium, copper and zinc in tissue sections of the small intestine from eight-week-old BALB/c male mice that developed gastrointestinal acute radiation syndrome (GI-ARS) in response to exposure to 8 Gray of gamma rays. Seven days after irradiation, we found that the majority of the iron is localized as hot spots in the intercellular regions of the area surrounding crypts and stretching between the outer perimeter of the intestine and the surface cell layer of villi. In addition, this study represents our current efforts to develop elemental cell classifiers that could be used for the automated generation of regions of interest for analyses of X-ray fluorescence maps. Once developed, such a tool will be instrumental for studies of effects of radiation and other toxicants on the elemental content in cells and tissues. While XFM studies cannot be conducted on living organisms, it is possible to envision future scenarios where XFM imaging of single cells sloughed from the human (or rodent) intestine could be used to follow up on the progression of GI-ARS.


  • Open Access

    A Bayesian framework for pathway‐guided identification of cancer subgroups by integrating multiple types of genomic data

    by Zequn Sun, Dongjun Chung, Brian Neelon, Andrew Millar‐Wilson, Stephen P. Ethier, Feifei Xiao, Yinan Zheng, Kristin Wallace, Gary Hardiman

    In recent years, comprehensive cancer genomics platforms, such as The Cancer Genome Atlas (TCGA), provide access to an enormous amount of high throughput genomic datasets for each patient, including gene expression, DNA copy number alterations, DNA methylation, and somatic mutation. While the integration of these multi‐omics datasets has the potential to provide novel insights that can lead to personalized medicine, most existing approaches only focus on gene‐level analysis and lack the ability to facilitate biological findings at the pathway‐level. In this article, we propose Bayes‐InGRiD (Bayesian Integrative Genomics Robust iDentification of cancer subgroups), a novel pathway‐guided Bayesian sparse latent factor model for the simultaneous identification of cancer patient subgroups (clustering) and key molecular features (variable selection) within a unified framework, based on the joint analysis of continuous, binary, and count data. By utilizing pathway (gene set) information, Bayes‐InGRiD does not only enhance the accuracy and robustness of cancer patient subgroup and key molecular feature identification, but also promotes biological understanding and interpretation. Finally, to facilitate an efficient posterior sampling, an alternative Gibbs sampler for logistic and negative binomial models is proposed using Pólya‐Gamma mixtures of normal to represent latent variables for binary and count data, which yields a conditionally Gaussian representation of the posterior. The R package “INGRID” implementing the proposed approach is currently available in our research group GitHub webpage (https://dongjunchung.github.io/INGRID/).